HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Young, G. Search for Related Content PubMed PubMed Citation Articles by Young, G. Social Bookmarking                   What's this?

New Anticoagulants in Children

Correspondence: Guy Young, MD, Children’s Hospital Los Angeles, 4650 Sunset Blvd., Mail Stop 54, Los Angeles, CA 90027; Phone: 323-361-4628; Fax: 323-361-7128; e-mail: gyoung{at}chla.usc.edu

Abstract

Thromboembolic complications are increasing in children and the use of anticoagulation has seen a dramatic increase despite the lack of randomized clinical trials. The most widely used agents in children are heparin, low-molecular-weight heparins (LMWH), and warfarin. These agents, however, have significant limitations that are exaggerated in children. Novel anticoagulants such as direct thrombin inhibitors and the selective factor Xa inhibitor, fondaparinux, have been approved for use in adults and have properties that suggest they may be safer and more efficacious than the standard agents; however, until recently, publications using these agents in children were limited to case reports. Recently, clinical trials for two direct thrombin inhibitors, bivalirudin and argatroban, have been completed and a clinical trial of fondaparinux is under way. This review will compare the standard agents with the novel agents and briefly review the results of the clinical trials.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?